{"id":794987,"date":"2024-12-16T07:33:25","date_gmt":"2024-12-16T12:33:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/"},"modified":"2024-12-16T07:33:25","modified_gmt":"2024-12-16T12:33:25","slug":"xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/","title":{"rendered":"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., Dec.  16, 2024  (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer.<\/p>\n<p>\u201cCaroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,\u201d said Ren\u00e9 Russo, Pharm.D., president and chief executive officer of Xilio. \u201cHer expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.\u201d<\/p>\n<p>Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics, Inc., where she oversaw all corporate legal and compliance matters, including capital markets and licensing transactions, clinical development and commercial launch activities, partnership\/collaboration management, and FDA and healthcare regulatory compliance matters. Previously, Ms. Hensley was a corporate associate in the Boston office of Latham &amp; Watkins, where she represented public and private companies in biotechnology and other industries across a range of capital markets and strategic transactions throughout their lifecycle. She received her B.A. in economics from the University of Texas at Austin and her J.D. from the Boston University School of Law.<\/p>\n<p>\u201cI am thrilled to join the Xilio team at this pivotal moment in the company&#8217;s growth and look forward to helping to advance Xilio\u2019s promising pipeline of novel, tumor-activated immuno-oncology therapies,\u201d said Ms. Hensley.<\/p>\n<p>\n        <strong>About Xilio Therapeutics<\/strong><br \/>\n        <br \/>Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecifics and immune cell engagers. Learn more by visiting\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Rcmj_XxpOoB1Awhr8g7u12JVBD9E4YP_-kTbLila8xF9bYSvmB68kQ_by8Zob-BlebIOFVQBzQW69byuoNCxB7Ft8tV65EgZLdpRUSTqnFImvYfbzv1-3p3bQ0C3-j61q-uHvDoE8PZIRo3NP56cC1xKm5ZgVVBsAKzG6KjcHHuo-UcI-8gSuA8R7iPJbHf9hyOxW9qJ3AMQAEm7sAiKen8-qpxskZfcA3YGAzU3LQRrxkUXjkdNfu2XVX4Ytvx0ag5L_Q3TOK189FG7En3jYMMTMgLxZmKfHXhLQ_Lz5gcM3EMUT7Ge5WnD4cpp0Xvve6eDveXzFpz2xQxWsojoxV30Mmz_0ZHlpwL1m5Db9sK0sfmKb9a-gGTxq1vHSlcOfM7ajrqUMzmfQk6N0CNQzLccxow2IySy9jEdIP5yE3g=\" rel=\"nofollow\" target=\"_blank\">www.xiliotx.com<\/a>\u00a0and follow us on LinkedIn (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ugHGePchza8CpH2yUbSo_sSoIh2TCFaNb_-rHiM4RSupo7F37saeSkX-twpMdMnVnH-CCRNQD6KFDOrAlHEANcAV1um6XeCoZBQZvWabs7KY8fRR4EC8elRHmWSaAeJuNccOzXaBhs7_wNIVaIRILP-BGCGnBn19kI0ns9dKv3XdRwyq5k5Q_oGd60hBCcnUY4jQDEvq3UCxrfiXbqn_6fCT9M6a4yhThmMUz3c27evfFJe4Rn_yMcnrjo3Oq64iJQwtQieBXFPTCePygawJUj3N30fGlBiB8O18GpkYu_LZK_4jZZVxhWCShsxfTx77IxSytBC9N5BsKU5dY9spLSDgUcgTJNUqF2dDWcJq8fwO_Swkl-mKpyYUtkIgFnvPi4CQdCd8GaUrInzr2lbRmoucQYIrSiZ6Uuv2w4gDXT5Ljbs425gEer86CmnEcj1yhgQvD4zk0qgneHfhlXVGJ8r3lP7VCpxZr2hx5gsaCiu0H7dw1wXYhtDG3AQb5gS1eWUZ0JE9namfoG8gDQhuGs_swzWyiq_u3xI6hDKzuqechanmvzcb_eL7ofw8O1f3LsLcR40ReY7z0Gm84PdR1A==\" rel=\"nofollow\" target=\"_blank\">Xilio Therapeutics, Inc<\/a>.).<\/p>\n<p>This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.<\/p>\n<p>\n        <strong>Investor and Media Contact\u00a0<\/strong><br \/>\n        <br \/>Scott Young<br \/>Vice President, Investor Relations and Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gf1_Lnyt4l9Gv9RIDhj35329JBO7Eam2gnuoZkrj5pXrajH3H0LGO9ZjaMdv1u6uSsgSpP5nxSY0FzkHGoCMN9lvoM7VVb0k2Gd2GjsSL2YqZr4HIUR73z6xFRgnz_Sl3ctEosyTrwMvtWW19SxyA3qOGX9hNHEUgCAJJyCnTJVGvaiGN4eYF3ul_-G-00ZRegrL7HNSO8u3QLf6Wq-35VzXnhnw7z96OhricR9yW4GTSUuBjfSzI-Xcq10NeDbLVrcSQgQr4tHJTckAQIQxBbrEn7og8AIGQNn2Uonb97NCFSkUkvSFY9-vfky7daQamcjTRZ0CfJb3ZgNXtdtj-2a697BO4Wg6hC4Or2VzU_0P1fl6ckz0EnoLH2YYRUeWIIVgHG1BjaBRd960KcOwH28mT42AONQ_ud9tFeogloYUrRVTsF0a0Pr7GPC-fkvtkUMAqoexFkJzQwOpt4blC_X9U9-fBK3xnR9NOg457kU=\" rel=\"nofollow\" target=\"_blank\">investors@xiliotx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWExMjIzYTktZmI0Zi00M2I4LTk5NWItOGVjMjk4MjNhMDU1LTEyMjEzNTc=\/tiny\/Xilio-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. \u201cCaroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,\u201d said Ren\u00e9 Russo, Pharm.D., president and chief executive officer of Xilio. \u201cHer expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.\u201d Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics, Inc., where &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-794987","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. \u201cCaroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,\u201d said Ren\u00e9 Russo, Pharm.D., president and chief executive officer of Xilio. \u201cHer expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.\u201d Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics, Inc., where &hellip; Continue reading &quot;Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-16T12:33:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer\",\"datePublished\":\"2024-12-16T12:33:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/\"},\"wordCount\":389,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/\",\"name\":\"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=\",\"datePublished\":\"2024-12-16T12:33:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/","og_locale":"en_US","og_type":"article","og_title":"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - Market Newsdesk","og_description":"WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. \u201cCaroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,\u201d said Ren\u00e9 Russo, Pharm.D., president and chief executive officer of Xilio. \u201cHer expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.\u201d Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics, Inc., where &hellip; Continue reading \"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-16T12:33:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer","datePublished":"2024-12-16T12:33:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/"},"wordCount":389,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/","name":"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=","datePublished":"2024-12-16T12:33:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTQ1OSM2NjM4MTI1IzIyMDk4MDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=794987"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794987\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=794987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=794987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=794987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}